Clinical Trials Logo

Dermatitis clinical trials

View clinical trials related to Dermatitis.

Filter by:

NCT ID: NCT05369403 Active, not recruiting - Atopic Dermatitis Clinical Trials

A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab

ADapt
Start date: December 19, 2022
Phase: Phase 3
Study type: Interventional

The study will assess the safety and efficacy of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD) previously treated with Dupilumab.

NCT ID: NCT05363904 Recruiting - Atopic Dermatitis Clinical Trials

Atopic Dermatitis: Sub-Saharan Africa vs. Central Europe

Start date: March 30, 2022
Phase:
Study type: Observational

Many people are affected by atopic dermatitis (AD) worldwide. However, clinical studies on AD in Sub-Saharan Africa are rare and there is a lack of knowledge about possible differences in pathogenesis between European and African AD. This study will collect clinical and laboratory data with the aim to compare clinical characteristics and immune responses in AD patients in Sub-Saharan Africa and Central Europe. Furthermore, relevant allergens as well as the nasal, skin and gut micro- and mycobiome will be investigated.

NCT ID: NCT05340673 Recruiting - Clinical trials for Invasive Breast Carcinoma

Comparing Supplemental Topical Agents for the Treatment of Acute Radiation Dermatitis in Patients With Breast Cancer

Start date: June 21, 2022
Phase: Phase 1
Study type: Interventional

This clinical trial compares two supplemental topical agents (Aquaphor and Miaderm) for the treatment of acute radiation dermatitis in patients with breast cancer undergoing radiation therapy. Radiation dermatitis is a radiation-induced skin reaction which can cause itching, swelling, pain, and general discomfort. Aquaphor is a commonly available, inexpensive, petrolatum-based multi-purpose ointment designed to protect and sooth extremely dry skin, chapped lips, cracked hands and feet, minor cuts and burns, and many other skin irritations. Miaderm is a water-based cream and contains ingredients like calendula, hyaluronate, and aloe vera which may help reduce occurrence and severity of radiation dermatitis. Both are commonly recommended and used by breast cancer patients undergoing external beam radiation therapy (EBRT). However, it is not known whether one is better than the other in treating or preventing radiation dermatitis.

NCT ID: NCT05339750 Completed - Clinical trials for Allergic Contact Dermatitis

Allergy Skin Patch Artificial Intelligence (AI)

Start date: February 15, 2022
Phase: N/A
Study type: Interventional

The purpose of this research is to assess human and artificial intelligence performance in grading contact dermatitis reactions in healthy volunteers.

NCT ID: NCT05330637 Recruiting - Asthma Clinical Trials

Study on the Influence of Climatic and Environmental Factors on Respiratory Diseases in Sanya, Hainan Province, China.

Start date: March 3, 2022
Phase:
Study type: Observational

To investigate the Influence of Climatic and Environmental Factors on Respiratory or Allergic Diseases in Sanya.

NCT ID: NCT05326672 Recruiting - Atopic Dermatitis Clinical Trials

Phase III Clinical Study of Benvitimod Cream in the Treatment of Mild to Moderate Atopic Dermatitis

Start date: April 2022
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blind, multicenter, placebo-controlled clinical Phase III study to evaluate the safety and efficacy of Benvitimod cream, 1% twice daily for the treatment of mild to moderate atopic dermatitis. Approximately 240 participants with mild to moderate atopic dermatitis will be enrolled and randomly divided into two groups in a 2:1 ratio. They will use either the Benvitimod cream or placebo at the skin with atopic dermatitis for 8 weeks.

NCT ID: NCT05324618 Completed - Dermatitis Clinical Trials

Tacrolimus Versus Hydrocortisone in Atopic Dermatitis

Start date: May 15, 2022
Phase: Phase 4
Study type: Interventional

Atopic dermatitis (AD) is a very common inflammatory, genetic skin disorder that occurs more frequently in children. Its exact etiology is not known but it is characterized by pruritic skin reactions with elevation in the levels of inflammatory markers. Corticosteroids are the first line and the mainstay therapy in management of atopic dermatitis but have many local and systemic adverse effects. The study aims to evaluate the efficacy and safety of topical tacrolimus ointment in comparison to topical hydrocortisone cream in management of children diagnosed with atopic dermatitis.

NCT ID: NCT05319444 Recruiting - Hair Loss Clinical Trials

Cleansing Device for the Treatment of Scalp and Hair Conditions

Start date: June 30, 2022
Phase: N/A
Study type: Interventional

The objective of this study is to evaluate an improvement of scalp health after the use of an investigational off-label WaterPik and brush device aimed to massage and cleanse the scalp.

NCT ID: NCT05318300 Active, not recruiting - Atopic Dermatitis Clinical Trials

Evaluation of an Adapted Formula on Atopic Dermatitis.

Start date: May 24, 2022
Phase: N/A
Study type: Interventional

The aim of this study is to show the efficiency of a new infant formula containing fiber on the management of moderate to severe atopic dermatitis.

NCT ID: NCT05316805 Recruiting - Clinical trials for Atopic Dermatitis Eczema

China Type II Inflammatory Skin Disease Clinical Research and Standardized Diagnosis and Treatment Project

CORNERSTONE
Start date: August 31, 2021
Phase:
Study type: Observational

In order to further improve the diagnosis and treatment level of type 2 inflammatory skin diseases, the National Clinical Center for Skin and Immune Diseases established a standardized diagnosis and treatment center for type 2 inflammatory skin diseases to systematically and effectively understand the current treatment status of patients with type 2 inflammatory skin diseases, as well as the efficacy and safety of various treatment methods during practices, so as to further improve the diagnosis and treatment level of type 2 inflammatory skin diseases and help patients with type 2 inflammatory skin diseases.